Introduction
============

Yes-associated protein (YAP), along with the transcriptional co-activator TAZ, is a main downstream effector of the Hippo pathway, which regulates tissue homeostasis, organ size, regeneration and tumorigenesis ([@b1-or-37-05-2620]). In mammalian systems, the Hippo pathway is composed of the core kinase complexes mammalian Ste2-like kinases 1/2 and large tumor suppressor kinases 1/2 ([@b2-or-37-05-2620]). The main function of the Hippo pathway is to negatively regulate the activity of YAP and TAZ, to promote cellular proliferation, and to induce anti-apoptotic genes via interactions with various transcription factors ([@b2-or-37-05-2620]--[@b4-or-37-05-2620]). When the Hippo pathway is active, the inhibitory mammalian Ste2-like kinases/large tumor suppressor kinases phosphorylate YAP and TAZ. Phosphorylation leads to nuclear exclusion of YAP and TAZ. Then, YAP and TAZ are sequestered and subjected to proteasomal degradation in the cytoplasm; also, gene expression of YAP- and TAZ-driven molecules is suppressed ([@b4-or-37-05-2620],[@b5-or-37-05-2620]).

Overexpression of YAP1 has been found in various types of cancers ([@b6-or-37-05-2620]--[@b9-or-37-05-2620]), and may lead to oncogenic transformation of immortalized epithelial cells ([@b10-or-37-05-2620]). The expression and role of YAP1 in cancer is cell type-dependent ([@b11-or-37-05-2620],[@b12-or-37-05-2620]). Overexpression of YAP was observed in 62% of hepatocellular carcinomas and 72.6% of colorectal cancers, and was found to be an independent predictor associated with poor disease-free survival and overall survival ([@b13-or-37-05-2620]). In 66.3% of non-small cell lung cancers, YAP was found to be overexpressed, and was associated with reduced overall survival ([@b14-or-37-05-2620]). Several studies reported that YAP1 is overexpressed in ovarian cancer ([@b6-or-37-05-2620]) and acts as an oncogene ([@b15-or-37-05-2620]). Zhang *et al* reported that high levels of nuclear YAP1 correlate with poor prognosis in ovarian cancer patients with clear cell carcinoma ([@b15-or-37-05-2620]). Another study showed that YAP1 is highly expressed in serous/endometrioid cystadenocarcinomas, and is positively associated with patient prognosis ([@b16-or-37-05-2620]). However, the role of YAP1 as an oncogene has not yet been fully investigated in a large group of ovarian serous cystadenocarcinoma (OSC) patients, who account for the largest proportion of malignant ovarian cancer cases ([@b17-or-37-05-2620],[@b18-or-37-05-2620]). Therefore, in the present study, we investigated the expression of YAP1 and determined its clinical significance in OSC.

Materials and methods
=====================

### Gene expression profiles

Level 3 mRNA expression data from 8 normal and 590 OSC samples were obtained from the TCGA data portal (<https://tcga-data.nci.nih.gov/tcga/>).

### Analysis of mRNA microarray data

The raw data was initially analyzed using R software (v.3.2.5; <http://www.r-project.org/>). The chip data was normalized using the RankNormalize module in GenePattern (<http://www.broadinstitute.org/cancer/software/genepattern>). GeneNeighbors and ClassNeighbors, modules programmed in GenePattern (<http://www.broadinstitute.org/cancer/software/genepattern>), were used to select genes closely related to YAP1 ([@b19-or-37-05-2620]). cBioportal (<http://www.cbioportal.org/>) was also used to analyze cross-cancer alterations in YAP1.

### Functional enrichment analysis

The DEGs were imported into the Database for Annotation, Visualization and Integrated Discovery (<http://david.abcc.ncifcrf.gov/>) ([@b20-or-37-05-2620]) in order to perform Gene Ontology (GO) functional enrichment analysis. Gene set enrichment analysis (GSEA) was used to enrich the mRNAs predicted to have a correlation with pathway in C2, curated gene set enrichment analysis ([@b21-or-37-05-2620],[@b22-or-37-05-2620]). GO analysis encompasses 3 domains: biological processes, cellular components and molecular functions. P\<0.05 was considered to indicate statistical significance.

### Statistical analysis

The distributions of characteristics between the 2 groups were compared using the t-test for continuous variables (or the Kolmogorov-Smirnov test when the expected frequency within any cell was \<5), and the χ^2^ test (or Fisher\'s exact test when the expected frequency within any cell was \<5) for categorical variables. The distributions of characteristics between 3 or more groups were compared using ANOVA. Cumulative event (death) rate was calculated by the Kaplan-Meier method, using the time to the first event as the outcome variable. Probability of and calculated risk for recurrence were determined by actuarial analysis. The criteria for statistical analysis were date of operation and date of death. Survival curves were compared by the log-rank test for various recurrence factors and Cox\'s model for multivariate analysis. A P-value of\<0.05 was considered statistically significant. Statistical analyses were performed using the Prism 5.0 software (GraphPad Prism Software, La Jolla, CA, USA), and the Statistical Package for Social Sciences for Windows (SPSS, Inc., Chicago, IL, USA).

Results
=======

### Cross-cancer mRNA expression and alterations in the YAP1 gene

YAP1 mRNA expression in cases of OSC was higher than in 21 other cancer types recorded in the TCGA database. mRNA expression of YAP1 was lowest in acute myeloid leukemia ([Fig. 1](#f1-or-37-05-2620){ref-type="fig"}). Cross-cancer alteration was investigated in 21 types of cancer, and YAP1 expression in OSC was the greatest among the 21 types of cancers recorded in the TCGA.

### YAP1 mRNA expression in OSC

The present study examined YAP1 mRNA expression in OSC compared with 8 normal control samples ([Fig. 2](#f2-or-37-05-2620){ref-type="fig"}). Clinicopathological information of the patients is shown in [Table I](#tI-or-37-05-2620){ref-type="table"}. YAP1 mRNA expression was significantly higher in cases of OSC compared to normal controls ([Fig. 2A](#f2-or-37-05-2620){ref-type="fig"}). YAP1 mRNA expression was higher in stages III and IV compared to earlier stages ([Fig. 2B](#f2-or-37-05-2620){ref-type="fig"}). When comparing YAP1 mRNA expression in 4 subtypes of ovarian cancer, differentiated, immunoreactive, mesenchymal and proliferative, and in 2 subtypes of ovarian cancer, integrated mesenchymal and epithelial subtypes ([@b23-or-37-05-2620],[@b24-or-37-05-2620]), YAP1 mRNA expression in the proliferative subtype was significantly higher than that in the differentiated, immunoreactive and mesenchymal subtypes ([Fig. 2C](#f2-or-37-05-2620){ref-type="fig"}). However, there was no significant difference in expression between the integrated mesenchymal subtype vs. the integrated epithelial subtype ([Fig. 2D](#f2-or-37-05-2620){ref-type="fig"}).

### YAP1 protein expression in OSC

When a comparison was conducted between stages of ovarian cancer, YAP1 protein expression was only significantly higher in stage IV compared to stages I, II and III ([Fig. 3A](#f3-or-37-05-2620){ref-type="fig"}). The proliferative and differentiated subtypes showed significantly higher protein expression than did the immunoreactive subtype ([Fig. 3B](#f3-or-37-05-2620){ref-type="fig"}). However, there was no significant difference in YAP1 protein level between the integrated epithelial and mesenchymal subtypes ([Fig. 3C](#f3-or-37-05-2620){ref-type="fig"}). The phosphorylated form of YAP1, at serine 127 (pYAP), which is inactivate and is localized to the cytoplasm, did not show any significant differences in protein expression ([Fig. 3D](#f3-or-37-05-2620){ref-type="fig"}). pYAP in the immunoreactive subtype was significantly lower than that in other subtypes; however, the pYAP/YAP ratio, which indicates higher YAP1 activity when it is lower, was lower in stage III than in stage I ([Fig. 3E and G](#f3-or-37-05-2620){ref-type="fig"}). There was no significant difference in the pYAP/YAP ratio between the subtypes of ovarian cancer ([Fig. 3H and I](#f3-or-37-05-2620){ref-type="fig"}).

### GeneNeighbors of YAP1

The range of YAP1 mRNA expression in the 590 OSC samples was 2.12 (log~2~) to 9.78 (log~2~), with a fold-change of 4.61. The 100 genes that were most highly correlated with YAP1 were selected using GeneNeighbors ([Fig. 4A](#f4-or-37-05-2620){ref-type="fig"}), and classified using DAVID. The genes were classified into 3 groups based on biological processes, cellular components and molecular functions. GO terms with significant differences (P\<0.05) were: i) biological process, ii) cellular components, and iii) molecular functions. Genes highly expressed in OSC were mainly associated with the cell cycle (cell cycle process, cell cycle and cell cycle phase) and protein complexes (protein localization, protein complex biogenesis and protein complex assembly) when analyzed by biological process ([Fig. 4B](#f4-or-37-05-2620){ref-type="fig"}). Genes highly expressed in OSC were mainly associated with the cytosol and ubiquitin ligase complexes when analyzed by cellular components. Genes highly expressed in OSC were mainly associated with ATP-dependent peptidase activity when analyzed by molecular function. In addition, when genes were analyzed according to cell signaling pathway \[Kyoto Encyclopedia of Genes and Genomes (KEGG)\], 5 signaling pathways had significant P-values. The analysis illustrated the importance of the ATM signaling pathway, the role of BRCA1, BRCA2 and ATR in cancer susceptibility, the Cdc25 and Chk1 regulatory pathways that respond to DNA damage, regulation of cell cycle progression by Plk3, and RB tumor-suppressor/checkpoint signaling in response to DNA damage.

### ClassNeighbors of YAP1 upregulated and downregulated in OSC

Analysis using ClassNeighbors yielded 2 classes of OSC: Class A contained the top 59 (10%) YAP1-upregulated OSC samples and Class B contained the 59 (10%) most YAP1-downregulated OSC samples ([Fig. 5A](#f5-or-37-05-2620){ref-type="fig"}). Of the 17,814 probe sets, the 200 genes that were most strongly correlated and most highly expressed in Classes A and B were selected. DAVID analysis classified these genes into groups based on GO terms: i) biological processes, ii) cellular components, iii) molecular functions, and iv) the KEGG pathway ([Fig. 5B and C](#f5-or-37-05-2620){ref-type="fig"} and [Table II](#tII-or-37-05-2620){ref-type="table"}). Genes highly expressed in Class A were mostly associated with DNA recombination and the cell cycle (biological processes), intracellular organelle lumen (cellular components), and RNA and nucleotide binding (molecular functions) ([Fig. 5B](#f5-or-37-05-2620){ref-type="fig"}). Genes highly expressed in Class B were mostly associated with nucleosome and chromatin assembly (biological processes), nucleosomes and the respiratory chain (cellular components), and NADH dehydrogenase (molecular functions) ([Fig. 5C](#f5-or-37-05-2620){ref-type="fig"}).

In addition, GSEA was performed in order to investigate the significantly enriched pathways that differed between Classes A and B. In Class A, pathways involving tight junctions, endometrial cancer, WNT signaling, TGF-β signaling, adherent junctions, basal cell carcinoma and prostate cancer were significantly enriched when compared with Class B. In Class B, pathways involved with primary immunodeficiency, systematic lupus erythematosus, the intestinal immune network for IgA production, regulation of autophagy, autoimmune thyroid disease and natural killer cell-mediated cytotoxicity were enriched ([Table III](#tIII-or-37-05-2620){ref-type="table"}). In Class A, WNT ([@b25-or-37-05-2620]) and TGF-β signaling ([@b26-or-37-05-2620]) were related to cancer progression ([Fig. 6A](#f6-or-37-05-2620){ref-type="fig"}). Immune-related signaling pathways were related to Class B ([Fig. 6B](#f6-or-37-05-2620){ref-type="fig"}).

### Survival analysis

In order to determine the prognostic significance of YAP1 expression in patients with OSC, we assessed the correlation between YAP mRNA and protein expression profiles and clinically significant characteristics: survival, tumor stage, grade and residual disease status. Initially, Kaplan-Meier curves were used to plot overall survival in samples with mRNA expression that was either 2-fold upregulated or downregulated ([Fig. 7](#f7-or-37-05-2620){ref-type="fig"}). YAP1 mRNA expression was not significantly associated with patient prognosis in OSC ([Fig. 7A](#f7-or-37-05-2620){ref-type="fig"}). To determine whether YAP and pYAP distribution are associated with overall patient survival in OSC, YAP and pYAP expression levels were categorized as high, intermediate and low, since neither YAP nor pYAP alone were associated with OSC prognosis. Among 9 categories studied, the category of high YAP and low pYAP showed the poorest prognosis ([Fig. 7B](#f7-or-37-05-2620){ref-type="fig"}). The category of high YAP and low pYAP showed significantly poorer prognosis than did the category of high YAP and high pYAP and the category of intermediate YAP and intermediate pYAP ([Fig. 7C and D](#f7-or-37-05-2620){ref-type="fig"}).

Discussion
==========

In the present study, alterations in the YAP1 gene in cases of OSC were found to be higher than that in various other cancer types. YAP1 mRNA expression was significantly higher in OSC compared with normal ovarian samples, and was higher in stages III and IV than in stages I and II. YAP1 protein, which mainly localized to the nucleus, was also expressed more highly in stage IV than in stages I, II and III. However, the protein level of pYAP1, which is localized to the cytoplasm, was not significantly different between stages. The ratio of pYAP/YAP, which indicates higher activity at a low ratio, was lower in stage III than in stages I and II. When considering OSC subtypes, YAP1 mRNA and protein expression in the proliferative subtype was significantly higher than that in the differentiated, immunoreactive and mesenchymal subtypes. However, there was no significant difference in YAP1 mRNA or protein expression between the integrated mesenchymal and the integrated epithelial subtypes. In bioinformatic analysis, YAP1 was mainly correlated with the cell cycle. TGF-β and WNT signaling were significantly increased in the high-YAP1 class as assessed by gene set enrichment analysis. Finally, high-YAP and low-pYAP were associated with poor overall survival in cases of OSC.

Elevated YAP1 expression and nuclear localization have been observed in multiple types of human cancers, including liver, colon, lung and prostate cancer ([@b6-or-37-05-2620]--[@b8-or-37-05-2620],[@b27-or-37-05-2620]). In hepatocellular carcinoma, YAP1 was found to be an independent prognostic marker for overall and disease-free survival ([@b13-or-37-05-2620]). In epithelial ovarian cancer, subcellular levels of YAP1 showed an exceptionally strong association with poor prognosis; high levels of nuclear YAP or low levels of cytoplasmic phosphorylated YAP1 were associated with poor prognosis ([@b28-or-37-05-2620]). Patients with both high levels of nuclear YAP and low levels of phosphorylated YAP had an \~50% lower 5-year survival rate, and this combination served as an independent prognostic marker for survival ([@b28-or-37-05-2620]). In accordance with previous findings, we showed that high YAP and low pYAP were associated with a poor prognosis. High YAP1 expression and its subcellular distribution may be related to poor overall survival in OSC. This finding should be confirmed in further studies.

The Cancer Genome Atlas Research Network separates OSC into 4 subtypes (immunoreactive, differentiated, proliferative and mesenchymal) based on mRNA analysis ([@b24-or-37-05-2620]). Yang *et al* found that the integrated epithelial and mesenchymal subtypes were associated with poor overall survival based on miRNA analysis of OSC patients ([@b23-or-37-05-2620]). In the present study, we revealed that YAP1 mRNA and protein expression in the proliferative subtype was significantly higher than that in the differentiated, immunoreactive and mesenchymal subtypes. However, there was no significant difference in YAP1 mRNA and protein expression between the integrated mesenchymal subtype and the integrated epithelial subtype. Molecular subgroups of ovarian cancer have been poorly examined and need to be further elucidated.

To verify the involvement of YAP1 in OSC, we performed bioinformatic analysis. This analysis revealed that cell cycle- and protein localization-related genes were highly correlated with YAP1 in 563 OSC patient samples ([Fig. 4A](#f4-or-37-05-2620){ref-type="fig"}). In addition, ClassNeighbors analysis classified YAP1-expressing OSC into Class A, which expresses genes associated with DNA recombination, cell cycle and RNA binding ([Fig. 5B](#f5-or-37-05-2620){ref-type="fig"}) and Class B, which expresses genes associated with nucleosome assembly, the respiratory chain, and NADH dehydrogenase activity ([Fig. 5C](#f5-or-37-05-2620){ref-type="fig"}). Class A genes enhance cell cycle-related functions, while Class B genes enhance nucleosome and oxidative phosphorylation pathways. GSEA was performed to investigate significantly enriched pathways that differed between Classes A and B. In Class A, pathways involving tight junctions, WNT and TGF-β signaling, and adherens junctions were more active than they were in Class B. In Class B, pathways involving primary immunodeficiency, systematic lupus erythematosus, intestinal immune network for IgA production, regulation of autophagy, and natural killer cell-mediated cytotoxicity were enriched ([Table III](#tIII-or-37-05-2620){ref-type="table"}). In Class A, WNT signaling ([@b25-or-37-05-2620]) and TGF-β signaling ([@b26-or-37-05-2620]) were related to cancer progression.

In conclusion, we investigated alterations in YAP1 gene expression in OSC, which was higher than that in 20 other types of cancers. mRNA expression and protein levels of YAP1 were significantly higher in advanced-stage OSC. High YAP and low pYAP were significantly correlated with poor prognosis in OSC. High YAP expression level and also its subcellular distribution may be associated with overall patient survival in OSC.
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![Cross-cancer mRNA expression of YAP1. (A) The data depict the mRNA expression of YAP1 in different cancer types based on the TCGA (<https://tcga-data.nci.nih.gov/tcga/>) data portal. (B) The data depict the frequency of alterations in YAP1 across different cancer types based on the TCGA. Potential alterations include mutations, deletions, amplification or multiple alterations. Data were obtained from the cBio database for cancer genomics (<http://cbioportal.org/public-portal/>).](OR-37-05-2620-g00){#f1-or-37-05-2620}

![(A-D) YAP1 mRNA expression in ovarian serous adenocarcinonoma. mRNA microarray data of YAP1 in normal controls and ovarian serous cystadenocarcinoma patients, obtained from the TCGA data portal (<https://tcga-data.nci.nih.gov/tcga/>). mRNA microarray data of YAP1 in various cell types of epithelial ovarian carcinoma, obtained from the CCLE data portal (<http://www.broadinstitute.org/ccle/>); \*\*P\<0.01 and \*\*\*P\<0.001. One way ANOVA was performed for comparisons between more than 2 groups, and t-tests were performed for comparisons between 2 groups.](OR-37-05-2620-g01){#f2-or-37-05-2620}

![(A-I) YAP1 protein expression in ovarian serous adenocarcinonoma. Protein expression data of YAP1 in ovarian serous cystadenocarcinoma, obtained from the TCGA data portal (<https://tcga-data.nci.nih.gov/tcga/>); \*P\<0.05, \*\*P\<0.01 and \*\*\*P\<0.001. One way ANOVA was performed for comparisons between more than 2 groups, and t-tests were performed for comparisons between 2 groups.](OR-37-05-2620-g02){#f3-or-37-05-2620}

![GeneNeighbors of YAP1 in 590 ovarian serous cystadenocarcinoma samples. Hierarchical clustering of YAP1 GeneNeighbors in ovarian serous cystadenocarcinoma. Ovarian serous cystadenocarcinoma samples are arranged in decreasing order of YAP mRNA expression. Colors in the heat map represent expression relative to the mean expression value, with red indicating higher expression and blue indicating lower expression. (A) GeneNeighbors of YAP1 are shown in the column. (B) GeneNeighbors were characterized as biological processes, cellular components, molecular function and KEGG pathway-related.](OR-37-05-2620-g03){#f4-or-37-05-2620}

![ClassNeighbors of YAP1-related genes in 2 classes of ovarian serous cystadenocarcinoma samples. Hierarchical clustering of differentially expressed genes (top 10%) upregulated and downregulated in OSC cases according to Pearson distance. (A) Colors in the heat map represent expression relative to the mean expression value, with red indicating higher expression and blue indicating lower expression. (B and C) Genes in classes A and B were divided into biological processes, cellular components and molecular functions.](OR-37-05-2620-g04){#f5-or-37-05-2620}

![(A) GSEA analysis of Class A and B. WNT and TGF-β signaling were significantly enriched in Class A. (B) Hematopoietic cell lineage pathway and natural killer mediated cytotoxicity pathway were significantly enriched in Class B.](OR-37-05-2620-g05){#f6-or-37-05-2620}

![Survival analysis. High YAP and low pYAP protein expression were correlated with poor prognosis. Kaplan-Meier analysis of the association between YAP mRNA and protein expression, and overall survival. (A) Kaplan-Meier curves were used to plot overall survival with mRNA expression. YAP and pYAP expression levels were categorized as high, intermediate and low. (B) Among 9 categories, the category of high YAP and low pYAP showed the poorest prognosis. (C) P=0.042. (D) P=0.065. P-value was determined by log-rank tests.](OR-37-05-2620-g06){#f7-or-37-05-2620}

###### 

Clinicopathological information of the ovarian serous cystadenocarcinoma patients of The Cancer Genome Atlas (TCGA).

                     mRNA YAP expression   YAP protein expression   Phosphorylated YAP protein expression                                      
  ------------------ --------------------- ------------------------ --------------------------------------- ------ ------ ------ ------ ------ ------
  No. of patients    563                   205                      83                                      137    138    137    137    138    137
  Mean age (years)   59.7                  60.2                     58.8                                    61.1   59.7   61.3   61.7   58.5   58.9
  Stage                                                                                                                                        
    I                16                    9                        0                                       5      3      3      3      9      2
    II               27                    11                       4                                       6      7      8      10     4      7
    III              440                   152                      66                                      108    105    110    110    109    103
    IV               85                    30                       13                                      16     22     16     14     14     23
  Tumor grade                                                                                                                                  
    G1               6                     4                        0                                       1      0      2      2      2      1
    G2               65                    29                       7                                       15     20     16     15     17     22
    G3               478                   166                      75                                      112    117    118    117    116    113
  Surgical outcome                                                                                                                             
    Optimal          369                   125                      55                                      86     87     91     85     86     88
    Suboptimal       142                   56                       17                                      30     38     36     39     36     37
  Vital status                                                                                                                                 
    Living           269                   100                      37                                      60     65     61     62     66     67
    Deceased         291                   103                      45                                      76     73     75     75     71     68

###### 

DAVID analysis of ClassNeighbors.

  A, Class A                                                                                                                
  --------------------------------------------------------------------------------------------------------- ------- ------- ---------
  Biological process (BP)                                                                                                   
    GO:0006310\~DNA recombination                                                                             6     3.24    0.005
    GO:0022402\~cell cycle process                                                                          14      7.57    0.006
    GO:0007049\~cell cycle                                                                                  17      9.19    0.007
    GO:0044265\~cellular macromolecule catabolic process                                                    16      8.65    0.009
    GO:0030509\~BMP signaling pathway                                                                         4     2.16    0.011
    GO:0008104\~protein localization                                                                        18      9.73    0.011
    GO:0022403\~cell cycle phase                                                                            11      5.95    0.012
    GO:0000077\~DNA damage checkpoint                                                                         4     2.16    0.014
    GO:0009451\~RNA modification                                                                              4     2.16    0.014
    GO:0000075\~cell cycle checkpoint                                                                         5     2.70    0.015
    GO:0009057\~macromolecule catabolic process                                                             16      8.65    0.017
    GO:0031570\~DNA integrity checkpoint                                                                      4     2.16    0.017
    GO:0007126\~meiosis                                                                                       5     2.70    0.020
    GO:0051327\~M phase of meiotic cell cycle                                                                 5     2.70    0.020
    GO:0010719\~negative regulation of epithelial to mesenchymal transition                                   2     1.08    0.021
    GO:0051321\~meiotic cell cycle                                                                            5     2.70    0.021
    GO:0065003\~macromolecular complex assembly                                                             14      7.57    0.023
    GO:0007178\~transmembrane receptor protein serine/threonine kinase signaling pathway                      5     2.70    0.023
    GO:0007131\~reciprocal meiotic recombination                                                              3     1.62    0.026
    GO:0045596\~negative regulation of cell differentiation                                                   7     3.78    0.026
    GO:0015031\~protein transport                                                                           15      8.11    0.029
    GO:0010771\~negative regulation of cell morphogenesis involved in differentiation                         2     1.08    0.031
    GO:0045184\~establishment of protein localization                                                       15      8.11    0.031
    GO:0051276\~chromosome organization                                                                     11      5.95    0.032
    GO:0051222\~positive regulation of protein transport                                                      4     2.16    0.033
    GO:0050821\~protein stabilization                                                                         3     1.62    0.035
    GO:0043933\~macromolecular complex subunit organization                                                 14      7.57    0.036
    GO:0016567\~protein ubiquitination                                                                        5     2.70    0.037
    GO:0002377\~immunoglobulin production                                                                     3     1.62    0.039
    GO:0016071\~mRNA metabolic process                                                                        9     4.86    0.041
    GO:0002440\~production of molecular mediator of immune response                                           3     1.62    0.042
    GO:0006974\~response to DNA damage stimulus                                                               9     4.86    0.043
    GO:0032446\~protein modification by small protein conjugation                                             5     2.70    0.050
  Cellular component (CC)                                                                                                   
    GO:0070013\~intracellular organelle lumen                                                               33      17.84   0.000
    GO:0043233\~organelle lumen                                                                             33      17.84   0.000
    GO:0031974\~membrane-enclosed lumen                                                                     33      17.84   0.000
    GO:0031980\~mitochondrial lumen                                                                         10      5.41    0.000
    GO:0005759\~mitochondrial matrix                                                                        10      5.41    0.000
    GO:0000794\~condensed nuclear chromosome                                                                  5     2.70    0.001
    GO:0000793\~condensed chromosome                                                                          6     3.24    0.007
    GO:0005829\~cytosol                                                                                     22      11.89   0.009
    GO:0031981\~nuclear lumen                                                                               23      12.43   0.012
    GO:0030135\~coated vesicle                                                                                6     3.24    0.015
    GO:0000228\~nuclear chromosome                                                                            6     3.24    0.017
    GO:0044429\~mitochondrial part                                                                          12      6.49    0.020
    GO:0005694\~chromosome                                                                                  10      5.41    0.025
    GO:0005654\~nucleoplasm                                                                                 15      8.11    0.030
    GO:0042645\~mitochondrial nucleoid                                                                        3     1.62    0.033
    GO:0009295\~nucleoid                                                                                      3     1.62    0.033
    GO:0031090\~organelle membrane                                                                          17      9.19    0.041
    GO:0042175\~nuclear envelope-endoplasmic reticulum network                                                7     3.78    0.046
  Molecular function (MF)                                                                                                   
    GO:0003723\~RNA binding                                                                                 18      9.73    0.000
    GO:0000166\~nucleotide binding                                                                          33      17.84   0.011
    GO:0016866\~intramolecular transferase activity                                                           3     1.62    0.025
    GO:0042803\~protein homodimerization activity                                                             8     4.32    0.041
    GO:0016887\~ATPase activity                                                                               8     4.32    0.041
    GO:0019237\~centromeric DNA binding                                                                       2     1.08    0.047
                                                                                                                            
  B, Class B                                                                                                                
                                                                                                                            
  Term                                                                                                      Count   \%      P-value
                                                                                                                            
  Biological process (BP)                                                                                                   
    GO:0006334\~nucleosome assembly                                                                           7     3.91    0.000
    GO:0031497\~chromatin assembly                                                                            7     3.91    0.000
    GO:0034621\~cellular macromolecular complex subunit organization                                        13      7.26    0.000
    GO:0065004\~protein-DNA complex assembly                                                                  7     3.91    0.000
    GO:0034728\~nucleosome organization                                                                       7     3.91    0.000
    GO:0006091\~generation of precursor metabolites and energy                                              12      6.70    0.000
    GO:0022900\~electron transport chain                                                                      7     3.91    0.001
    GO:0006323\~DNA packaging                                                                                 7     3.91    0.001
    GO:0034622\~cellular macromolecular complex assembly                                                    11      6.15    0.002
    GO:0006812\~cation transport                                                                            15      8.38    0.002
    GO:0006333\~chromatin assembly or disassembly                                                             7     3.91    0.002
    GO:0006119\~oxidative phosphorylation                                                                     6     3.35    0.004
    GO:0045454\~cell redox homeostasis                                                                        5     2.79    0.004
    GO:0006811\~ion transport                                                                               17      9.50    0.006
    GO:0043281\~regulation of caspase activity                                                                5     2.79    0.009
    GO:0006120\~mitochondrial electron transport, NADH to ubiquinone                                          4     2.23    0.009
    GO:0052548\~regulation of endopeptidase activity                                                          5     2.79    0.011
    GO:0052547\~regulation of peptidase activity                                                              5     2.79    0.012
    GO:0015672\~monovalent inorganic cation transport                                                         9     5.03    0.018
    GO:0006917\~induction of apoptosis                                                                        9     5.03    0.019
    GO:0012502\~induction of programmed cell death                                                            9     5.03    0.019
    GO:0042981\~regulation of apoptosis                                                                     16      8.94    0.020
    GO:0042775\~mitochondrial ATP synthesis coupled electron transport                                        4     2.23    0.021
    GO:0042773\~ATP synthesis coupled electron transport                                                      4     2.23    0.021
    GO:0043067\~regulation of programmed cell death                                                         16      8.94    0.022
    GO:0010941\~regulation of cell death                                                                    16      8.94    0.023
    GO:0030001\~metal ion transport                                                                         11      6.15    0.024
    GO:0051336\~regulation of hydrolase activity                                                              9     5.03    0.025
    GO:0006813\~potassium ion transport                                                                       6     3.35    0.026
    GO:0022904\~respiratory electron transport chain                                                          4     2.23    0.029
    GO:0043933\~macromolecular complex subunit organization                                                 14      7.82    0.034
    GO:0042127\~regulation of cell proliferation                                                            15      8.38    0.035
    GO:0008285\~negative regulation of cell proliferation                                                     9     5.03    0.035
    GO:0043065\~positive regulation of apoptosis                                                            10      5.59    0.036
    GO:0007268\~synaptic transmission                                                                         8     4.47    0.037
    GO:0043068\~positive regulation of programmed cell death                                                10      5.59    0.037
    GO:0010942\~positive regulation of cell death                                                           10      5.59    0.038
    GO:0050728\~negative regulation of inflammatory response                                                  3     1.68    0.041
    GO:0044093\~positive regulation of molecular function                                                   12      6.70    0.043
    GO:0006325\~chromatin organization                                                                        9     5.03    0.044
    GO:0050727\~regulation of inflammatory response                                                           4     2.23    0.045
  Cellular component (CC)                                                                                                   
    GO:0000786\~nucleosome                                                                                    7     3.91    0.000
    GO:0070469\~respiratory chain                                                                             7     3.91    0.000
    GO:0032993\~protein-DNA complex                                                                           7     3.91    0.000
    GO:0005746\~mitochondrial respiratory chain                                                               6     3.35    0.000
    GO:0044429\~mitochondrial part                                                                          16      8.94    0.001
    GO:0044455\~mitochondrial membrane part                                                                   7     3.91    0.002
    GO:0019866\~organelle inner membrane                                                                    11      6.15    0.002
    GO:0005739\~mitochondrion                                                                               22      12.29   0.002
    GO:0005740\~mitochondrial envelope                                                                      12      6.70    0.003
    GO:0005743\~mitochondrial inner membrane                                                                10      5.59    0.003
    GO:0000785\~chromatin                                                                                     8     4.47    0.004
    GO:0031966\~mitochondrial membrane                                                                      11      6.15    0.006
    GO:0009897\~external side of plasma membrane                                                              7     3.91    0.007
    GO:0045271\~respiratory chain complex I                                                                   4     2.23    0.008
    GO:0005747\~mitochondrial respiratory chain complex I                                                     4     2.23    0.008
    GO:0030964\~NADH dehydrogenase complex                                                                    4     2.23    0.008
    GO:0031967\~organelle envelope                                                                          14      7.82    0.009
    GO:0031975\~envelope                                                                                    14      7.82    0.009
    GO:0009986\~cell surface                                                                                  9     5.03    0.023
    GO:0031090\~organelle membrane                                                                          19      10.61   0.023
    GO:0044427\~chromosomal part                                                                              9     5.03    0.039
  Molecular function (MF)                                                                                                   
    GO:0003954\~NADH dehydrogenase activity                                                                   4     2.23    0.010
    GO:0008137\~NADH dehydrogenase (ubiquinone) activity                                                      4     2.23    0.010
    GO:0050136\~NADH dehydrogenase (quinone) activity                                                         4     2.23    0.010
    GO:0005267\~potassium channel activity                                                                    6     3.35    0.013
    GO:0016655\~oxidoreductase activity, acting on NADH or NADPH, quinone or similar compound as acceptor     4     2.23    0.015
    GO:0047485\~protein N-terminus binding                                                                    4     2.23    0.043
    GO:0030955\~potassium ion binding                                                                         5     2.79    0.047

###### 

Gene set enrichment analysis (GSEA) of Class A and Class B.

  A, Class A                                                                
  --------------------------------------------------- ----- ------- ------- -------
  KEGG_TIGHT_JUNCTION                                 125   0.38    1.63    0.004
  KEGG_ENDOMETRIAL_CANCER                             52    0.49    1.67    0.014
  KEGG_WNT_SIGNALING_PATHWAY                          147   0.40    1.63    0.019
  KEGG_SELENOAMINO_ACID_METABOLISM                    23    0.55    1.62    0.025
  KEGG_LYSINE_DEGRADATION                             43    0.49    1.64    0.025
  KEGG_AMINOACYL_TRNA_BIOSYNTHESIS                    41    0.54    1.60    0.026
  KEGG_TGF_BETA_SIGNALING_PATHWAY                     82    0.42    1.57    0.028
  KEGG_ADHERENS_JUNCTION                              73    0.46    1.62    0.032
  KEGG_BASAL_CELL_CARCINOMA                           55    0.51    1.69    0.036
  KEGG_PROSTATE_CANCER                                87    0.37    1.48    0.049
                                                                            
  B, Class B                                                                
                                                                            
  KEGG_ARACHIDONIC_ACID_METABOLISM                    51    −0.43   −1.58   0.010
  KEGG_PRIMARY_IMMUNODEFICIENCY                       34    −0.61   −1.73   0.026
  KEGG_SYSTEMIC_LUPUS_ERYTHEMATOSUS                   114   −0.61   −1.86   0.027
  KEGG_HEMATOPOIETIC_CELL_LINEAGE                     79    −0.54   −1.71   0.029
  KEGG_ALPHA_LINOLENIC_ACID_METABOLISM                17    −0.54   −1.53   0.034
  KEGG_INTESTINAL_IMMUNE_NETWORK_FOR_IGA_PRODUCTION   43    −0.51   −1.60   0.038
  KEGG_REGULATION_OF_AUTOPHAGY                        32    −0.44   −1.51   0.039
  KEGG_AUTOIMMUNE_THYROID_DISEASE                     47    −0.54   −1.62   0.042
  KEGG_NATURAL_KILLER_CELL_MEDIATED_CYTOTOXICITY      128   −0.44   −1.57   0.043

ES, enrichment score; NES, normalized enrichment score; NOM p-val, norminal p-value.

[^1]: Contributed equally
